全文获取类型
收费全文 | 2847篇 |
免费 | 322篇 |
国内免费 | 18篇 |
专业分类
耳鼻咽喉 | 60篇 |
儿科学 | 87篇 |
妇产科学 | 56篇 |
基础医学 | 484篇 |
口腔科学 | 50篇 |
临床医学 | 388篇 |
内科学 | 565篇 |
皮肤病学 | 55篇 |
神经病学 | 163篇 |
特种医学 | 78篇 |
外科学 | 349篇 |
综合类 | 130篇 |
一般理论 | 4篇 |
预防医学 | 306篇 |
眼科学 | 51篇 |
药学 | 236篇 |
肿瘤学 | 125篇 |
出版年
2022年 | 18篇 |
2021年 | 22篇 |
2020年 | 20篇 |
2019年 | 35篇 |
2018年 | 42篇 |
2017年 | 45篇 |
2016年 | 51篇 |
2015年 | 58篇 |
2014年 | 68篇 |
2013年 | 97篇 |
2012年 | 142篇 |
2011年 | 140篇 |
2010年 | 83篇 |
2009年 | 86篇 |
2008年 | 128篇 |
2007年 | 115篇 |
2006年 | 119篇 |
2005年 | 131篇 |
2004年 | 105篇 |
2003年 | 92篇 |
2002年 | 109篇 |
2001年 | 70篇 |
2000年 | 94篇 |
1999年 | 87篇 |
1998年 | 67篇 |
1997年 | 54篇 |
1996年 | 39篇 |
1995年 | 43篇 |
1994年 | 30篇 |
1993年 | 42篇 |
1992年 | 54篇 |
1991年 | 52篇 |
1990年 | 49篇 |
1989年 | 56篇 |
1988年 | 60篇 |
1987年 | 60篇 |
1986年 | 67篇 |
1985年 | 49篇 |
1984年 | 50篇 |
1983年 | 49篇 |
1982年 | 25篇 |
1981年 | 25篇 |
1980年 | 23篇 |
1979年 | 24篇 |
1978年 | 26篇 |
1972年 | 27篇 |
1971年 | 19篇 |
1970年 | 24篇 |
1969年 | 22篇 |
1967年 | 20篇 |
排序方式: 共有3187条查询结果,搜索用时 15 毫秒
91.
Shah SH Crosslin DR Haynes CS Nelson S Turer CB Stevens RD Muehlbauer MJ Wenner BR Bain JR Laferrère B Gorroochurn P Teixeira J Brantley PJ Stevens VJ Hollis JF Appel LJ Lien LF Batch B Newgard CB Svetkey LP 《Diabetologia》2012,55(2):321-330
Aims/hypothesis
Insulin resistance (IR) improves with weight loss, but this response is heterogeneous. We hypothesised that metabolomic profiling would identify biomarkers predicting changes in IR with weight loss.Methods
Targeted mass spectrometry-based profiling of 60 metabolites, plus biochemical assays of NEFA, ??-hydroxybutyrate, ketones, insulin and glucose were performed in baseline and 6?month plasma samples from 500 participants who had lost ??4?kg during Phase I of the Weight Loss Maintenance (WLM) trial. Homeostatic model assessment of insulin resistance (HOMA-IR) and change in HOMA-IR with weight loss (?HOMA-IR) were calculated. Principal components analysis (PCA) and mixed models adjusted for race, sex, baseline weight, and amount of weight loss were used; findings were validated in an independent cohort of patients (n?=?22).Results
Mean weight loss was 8.67?±?4.28?kg; mean ?HOMA-IR was ?0.80?±?1.73, range ?28.9 to 4.82). Baseline PCA-derived factor 3 (branched chain amino acids [BCAAs] and associated catabolites) correlated with baseline HOMA-IR (r?=?0.50, p?0.0001) and independently associated with ?HOMA-IR (p?0.0001). ?HOMA-IR increased in a linear fashion with increasing baseline factor 3 quartiles. Amount of weight loss was only modestly correlated with ?HOMA-IR (r?=?0.24). These findings were validated in the independent cohort, with a factor composed of BCAAs and related metabolites predicting ?HOMA-IR (p?=?0.007).Conclusions/interpretation
A cluster of metabolites comprising BCAAs and related analytes predicts improvement in HOMA-IR independent of the amount of weight lost. These results may help identify individuals most likely to benefit from moderate weight loss and elucidate novel mechanisms of IR in obesity. 相似文献92.
93.
Hwang KK Chen X Kozink DM Gustilo M Marshall DJ Whitesides JF Liao HX Catera R Chu CC Yan XJ Luftig MA Haynes BF Chiorazzi N 《Blood》2012,119(7):e35-e44
B-cell chronic lymphocytic leukemia (B-CLL) is characterized by the clonal expansion of CD5-expressing B lymphocytes that produce mAbs often reactive with microbial or autoantigens. Long-term culture of B-CLL clones would permit the collection and characterization of B-CLL mAbs to study antigen specificity and of B-CLL DNA to investigate molecular mechanisms promoting the disease. However, the derivation of long-term cell lines (eg, by EBV), has not been efficient. We have improved the efficiency of EBV B-CLL transformation of CpG oligonucleotide-stimulated cells by incubating patient peripheral blood mononuclear cells in the presence of an irradiated mouse macrophage cell line, J774A.1. Using this approach, peripheral blood mononuclear cells isolated from 13 of 21 B-CLL patients were transformed as documented by IGHV-D-J sequencing. Four clones grew and retained CD5 expression in culture for 2 to 4 months. However, despite documentation of EBV infection by expression of EBNA2 and LMP1, B-CLL cells died after removal of macrophage feeder cells. Nevertheless, using electrofusion technology, we generated 6 stable hetero-hybridoma cell lines from EBV-transformed B-CLL cells, and these hetero-hybridomas produced immunoglobulin. Thus, we have established enhanced methods of B-CLL culture that will enable broader interrogation of B-CLL cells at the genetic and protein levels. 相似文献
94.
95.
AP Mishreki E Lim P Cranefield S Pascoe S Jackson DA Stell 《Annals of the Royal College of Surgeons of England》2013,95(5):349-352
Introduction
The results of surgical resection and palliative chemotherapy use in hilar cholangiocarcinoma (HC) have been well publicised but the proportion of patients able to undergo these treatments and the comparative outcomes in a population of patients with HC are less well known.Methods
Patients with HC were identified by review of all patients undergoing percutaneous cholangiography over a nine-year period (2002–2010) in a tertiary facility. The treatment undertaken and outcomes were recorded.Results
Overall, 68 patients were identified (37 female) with a median age of 70 years. Forty-five (66%) were treated solely by insertion of a metal stent (median survival 4.73 months) and nine (13%) also received palliative chemotherapy (median survival 13.7 months). Persisting jaundice after stent insertion was noted in 18 of 35 patients (51%) tested within one month of death. Fourteen patients (21%) underwent surgical resection (median survival 20.2 months).Conclusions
Patients undergoing surgical resection had significantly longer survival than those receiving only a palliative stent but not compared with those also receiving palliative chemotherapy, with short-term follow-up. Only a third of patients, however, receive active treatment (surgery or chemotherapy) and improvements in long-term biliary palliation are needed. 相似文献96.
Obesity markedly increases the risk of hypertension and cardiovascular disease, which may be related to activation of the sympathetic nervous system (SNS). Sympathetic overactivity directly and indirectly contributes to blood pressure (BP) elevation in obesity, including stimulation of the renin-angiotensin-aldosterone system (RAAS). The adipocyte-derived peptide leptin suppresses appetite, increases thermogenesis, but also raises SNS activity and BP. Obese individuals exhibit hyperleptinemia but are resistant to its appetite-suppressing actions. Interestingly, animal models of obesity exhibit preserved sympathoexcitatory and pressor actions of leptin, despite resistance to its anorexic and metabolic actions, suggesting selective leptin resistance. Disturbance of intracellular signaling at specific hypothalamic neural networks appears to underlie selective leptin resistance. Delineation of these pathways should lead to novel approaches to treatment. In the meantime, treatment of obesity-hypertension has relied on antihypertensive drugs. Although sympathetic blockade is mechanistically attractive in obesity-hypertension, in practice its effects are disappointing because of adverse metabolic effects and inferior outcomes. On the basis of subgroup analyses of obese patients in large randomized clinical trials, drugs such as diuretics and RAAS blockers appear superior in preventing cardiovascular events in obesity--hypertension. An underused alternative approach to obesity-hypertension is induction of weight loss, which reduces circulating leptin and insulin, partially reverses resistance to these hormones, decreases sympathetic activation and improves BP and other risk factors. Though weight loss induced by lifestyle is often modest and transient, carefully selected pharmacological weight loss therapies can produce substantial and sustained antihypertensive effects additive to lifestyle interventions. 相似文献
97.
Forde KA Haynes K Troxel AB Trooskin S Osterman MT Kimmel SE Lewis JD Lo Re V 《Journal of viral hepatitis》2012,19(4):271-277
Hepatitis C virus (HCV) infection is associated with systemic inflammation and metabolic complications that might predispose patients to atherosclerosis. However, it remains unclear if HCV infection increases the risk of acute myocardial infarction (MI). To determine whether HCV infection is an independent risk factor for acute MI among adults followed in general practices in the United Kingdom (UK), a retrospective cohort study was conducted in The Health Improvement Network, from 1996 through 2008. Patients ≥18 years of age with at least 6 months of follow-up and without a prior history of MI were eligible for study inclusion. HCV-infected individuals, identified with previously validated HCV diagnostic codes (n = 4809), were matched on age, sex and practice with up to 15 randomly selected patients without HCV (n = 71 668). Rates of incident MI among patients with and without a diagnosis of HCV infection were calculated. Adjusted hazard ratios were estimated using Cox proportional hazards regression, controlling for established cardiovascular risk factors. During a median follow-up of 3.2 years, there was no difference in the incidence rates of MI between HCV-infected and -uninfected patients (1.02 vs 0.92 events per 1000 person-years; P = 0.7). HCV infection was not associated with an increased risk of incident MI (adjusted HR, 1.10; 95% confidence interval [CI], 0.67-1.83). Sensitivity analyses including the exploration of a composite outcome of acute MI and coronary interventions yielded similar results (adjusted HR, 1.16; 95% CI, 0.77-1.74). In conclusion, HCV infection was not associated with an increased risk of incident MI. 相似文献
98.
99.
Cornel Burger Marique Aucamp Jan du Preez Richard K. Haynes Andile Ngwane Jeanetta du Plessis Minja Gerber 《Pharmaceutical research》2018,35(10):186
Purpose
The aim of this study was to formulate nano-emulsions comprising natural oils and the active pharmaceutical ingredients (APIs) clofazimine (CLF), artemisone (ATM) and decoquinate (DQ) in order to determine effectiveness of the nano-emulsions for topical delivery of the APIs. The APIs alone do not possess suitable physicochemical properties for topical drug delivery.Methods
Nano-emulsions were formulated with olive and safflower oils encapsulating the APIs. Skin diffusion and tape stripping studies were performed. By using the lactate dehydrogenase (LDH) assay, in vitro toxicity studies were carried out on immortalized human keratinocytes (HaCaT) cell line to determine cytotoxicities due to the APIs and the nano-emulsions incorporating the APIs.Results
The nano-emulsions were effective in delivering the APIs within the stratum corneum-epidermis and the epidermis-dermis, were non-cytotoxic towards HaCaT cell lines (p <?0.05) and inhibited Mycobacterium tuberculosis in vitro.Conclusion
Natural oil nano-emulsions successfully deliver CLF, ATM and DQ and in principle could be used as supplementary topical treatment of cutaneous tuberculosis (CTB).100.
Early impact of the ICD‐10‐CM transition on selected health outcomes in 13 electronic health care databases in the United States 下载免费PDF全文